search
Back to results

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Primary Purpose

Vascular Diseases, Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Sulodexide
Sponsored by
Chengdu University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vascular Diseases, Peripheral focused on measuring Radiofrequency ablation combined with sclerotherapy, varicose veins, Sulodexide

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age >18 years and <80 years, and able to understand the requirements of the study and provide informed consent and accept the exams and follow-up. C2 - C5 varicose veins / CVI Symptomatic primary GSV, SSV, or AASV incompetence, with reflux >0.5 seconds on color duplex, eligible for patients undergoing radiofrequency ablation plus sclerotherapy BMI<35 The skin color is within the normal range, and no obvious skin color unevenness or skin diseases affect the observed indicators. Exclusion Criteria: Acute superficial or deep vein thrombosis History of asthma and stroke There are skin diseases, scars, infections, and other conditions in the surgical area that affect the observation indicators Pregnancy Serious damage to liver and kidney function Severe obesity (BMI>35) and severe edema of the lower extremities Others are not eligible for intravenous radiofrequency ablation combined with sclerotherapy

Sites / Locations

  • Hospital of Chengdu University of Traditional Chinese Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Taking sulodexide

Not taking drug

Arm Description

Sixty patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were given Sulodexide softgels 250LSU twice a day for two months after surgery。

Sixty patients with varicose veins of the lower extremities who received radiofrequency ablation combined with sclerotherapy were selected and did not take sulodexide after surgery.

Outcomes

Primary Outcome Measures

Changes in pigmentation area and color depth over the three months after surgery.
Computer software(ImageJ and Brown pixel distribution histogram joint color deconvolution) is used to calculate and record the area of pigmentation and color depth and compare them at different times.
Changes in the incidence and hardness (Shore hardness) of fibrous induration in the three months after surgery.
The hardness of the fiber induration is calculated and recorded using a Shore hardness tester and compared at different times.The hardness should decrease as the hard knot softens。
Changes in the area of congestion in the three months after surgery.
Computer software(ImageJ) calculates and records the area of congestion and compares it at different times.

Secondary Outcome Measures

Changes in pain scores on a visual analogue scale over the three months postoperatively postoperative
Pain scores are recorded on a Visual Analogue Scale and compared at different times.The scale ranges from 1 to 10, and the higher the score, the more painful it is
Incidence of bleeding complications
Regularly review and follow up with patients for the incidence of bleeding complications.(Such as hematemesis, vomiting blood, melena, etc)

Full Information

First Posted
November 22, 2022
Last Updated
December 29, 2022
Sponsor
Chengdu University of Traditional Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05654233
Brief Title
The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy
Official Title
The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 1, 2023 (Anticipated)
Primary Completion Date
August 1, 2023 (Anticipated)
Study Completion Date
September 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chengdu University of Traditional Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate whether adding sulodexide to the patients with varicose veins who received radiofrequency ablation combined with sclerotherapy can reduce or improve the impact of adverse events。
Detailed Description
Chronic venous insufficiency(CVI)of the lower extremities is a commonly clinically syndrome。 It can manifest as telangiectasias (or spider veins), reticular veins, varicose veins(VVS), edema, pigmentation and/or eczema, liposomal sclerosis, white atrophy, and venous ulcers。 Patients often seek treatment for varicose veins because of cosmetic problems, pain, swelling, itching, ulcers, and other symptoms。 With the development of society, more and more patients require to choose local anesthesia, minimally invasive, and rapid recovery surgery. Radiofrequency ablation(RFA) combined with sclerotherapy is a treatment with a broad clinically applicable spectrum for varicose veins, ranging from the Great saphenous vein (GSV)trunk to telangiectases (or spider veins).US guidelines for treating varicose veins and chronic venous disease of the lower extremities recommend endovascular thermal ablation (including RFA) as safe and effective for treating saphenous venous insufficiency. Foam sclerotherapy is to close the diseased vein by mixing sclerosants with air in a particular proportion and injecting it into the venous blood vessels so that the vein generates artificial thrombus and fibrosis. Because of its simple, economical, and minimally invasive characteristics, it is widely used in clinical practice. Pigmentation, fibrous induration, and pain are the most common complications after RFA combined with sclerotherapy. Hyperpigmentation is a brownish discoloration of the skin due to extravasation of red blood cells and hemosiderin deposition。 Fibrous induration and pain are mainly caused by thrombosis, inflammation, and vascular fibrosis。 Sulodexide is an orally vasoactive drug consisting of 80% heparin sulfate + 20% corn sulfate, with antithrombotic, fibrinolytic, anti-inflammatory, endothelial protective, and vascular regulating properties. This agent is used in venous ulcers, prevents recurrent venous thromboembolism, and has a low incidence of bleeding complications. Clinical observation in our department found that adding sulodexide can reduce or improve the impact of adverse events after RFA combined with sclerotherapy。 The purpose of this study is to evaluate whether adding sulodexide to the patients with varicose veins who received RFA combined with sclerotherapy accelerates the dissipation of pigmentation and fibrosis。

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vascular Diseases, Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
Keywords
Radiofrequency ablation combined with sclerotherapy, varicose veins, Sulodexide

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A total of 120 patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were randomly divided into two groups。 Each group included 60 people, one group added sulodexide based on the conventional treatment process, and the other group was a control group. The recovery of adverse reactions after surgery in both groups was observed.
Masking
Participant
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Taking sulodexide
Arm Type
Experimental
Arm Description
Sixty patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were given Sulodexide softgels 250LSU twice a day for two months after surgery。
Arm Title
Not taking drug
Arm Type
No Intervention
Arm Description
Sixty patients with varicose veins of the lower extremities who received radiofrequency ablation combined with sclerotherapy were selected and did not take sulodexide after surgery.
Intervention Type
Drug
Intervention Name(s)
Sulodexide
Intervention Description
The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
Primary Outcome Measure Information:
Title
Changes in pigmentation area and color depth over the three months after surgery.
Description
Computer software(ImageJ and Brown pixel distribution histogram joint color deconvolution) is used to calculate and record the area of pigmentation and color depth and compare them at different times.
Time Frame
three months
Title
Changes in the incidence and hardness (Shore hardness) of fibrous induration in the three months after surgery.
Description
The hardness of the fiber induration is calculated and recorded using a Shore hardness tester and compared at different times.The hardness should decrease as the hard knot softens。
Time Frame
three months
Title
Changes in the area of congestion in the three months after surgery.
Description
Computer software(ImageJ) calculates and records the area of congestion and compares it at different times.
Time Frame
three months
Secondary Outcome Measure Information:
Title
Changes in pain scores on a visual analogue scale over the three months postoperatively postoperative
Description
Pain scores are recorded on a Visual Analogue Scale and compared at different times.The scale ranges from 1 to 10, and the higher the score, the more painful it is
Time Frame
three months
Title
Incidence of bleeding complications
Description
Regularly review and follow up with patients for the incidence of bleeding complications.(Such as hematemesis, vomiting blood, melena, etc)
Time Frame
three months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 years and <80 years, and able to understand the requirements of the study and provide informed consent and accept the exams and follow-up. C2 - C5 varicose veins / CVI Symptomatic primary GSV, SSV, or AASV incompetence, with reflux >0.5 seconds on color duplex, eligible for patients undergoing radiofrequency ablation plus sclerotherapy BMI<35 The skin color is within the normal range, and no obvious skin color unevenness or skin diseases affect the observed indicators. Exclusion Criteria: Acute superficial or deep vein thrombosis History of asthma and stroke There are skin diseases, scars, infections, and other conditions in the surgical area that affect the observation indicators Pregnancy Serious damage to liver and kidney function Severe obesity (BMI>35) and severe edema of the lower extremities Others are not eligible for intravenous radiofrequency ablation combined with sclerotherapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chunshui He, Doctor
Phone
18981885601
Email
chunshuihe@msn.com
Facility Information:
Facility Name
Hospital of Chengdu University of Traditional Chinese Medicine
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610000
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiahui Zhou, Master
Phone
15517943987
Email
15517943987@163.com

12. IPD Sharing Statement

Learn more about this trial

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

We'll reach out to this number within 24 hrs